티움바이오

321550KOSDAQ

57.8 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Tium Bio is a biopharmaceutical company founded by a team that successfully developed and licensed the FDA-approved hemophilia treatment Afstyla, focusing on R&D for rare and intractable diseases. The company develops both small-molecule synthetic drugs and biopharmaceuticals, with several drug candidates in clinical trials, including NCE401 and NBP604. In 2024, Tium Bio acquired Petraon Care Lab, a natural cosmetics OEM/ODM firm, and operates Protiom Science, a CDAO company providing specialized biopharmaceutical process development services.

Number of Employees

67people

Average Salary

57.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.76Industry Average 1.200.0Point

3.1x industry avg (risky)

ROE

-42.45Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

39.36Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲59.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.7% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
티움바이오 항암제, 美서 병용요법 특허
티움바이오의 면역항암제 후보물질 토스포서팁이 미국에서 병용요법 특허를 획득하여 항암제 시장에서의 경쟁력을 강화했다.
Positive
면역항암제 병용요법 美 특허…티움바이오 12%↑[특징주]
티움바이오의 면역항암제 후보물질 특허 등록 소식으로 주가가 급등했다.
Positive
티움바이오, 자회사 프로티움 상반기 매출 전년比 2배…SK플라즈마 지....
티움바이오의 핵심 자회사 프로티움사이언스의 상반기 매출이 전년 대비 두 배 이상 증가하며 성장을 이어가고 있으며, SK플라즈마 지분 가치 상승으로 투자자산 가치도 높게 평가되고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 4,725Won52-week high 13,14052-week low 3,680

1-month return3.0Point

1m 0.64% (flat)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14